Skin & hair

Tranexamic Acid for Melasma

Save

Melasma is notoriously resistant to a single fix, and tranexamic acid has become one of the newer additions to the toolkit for cases that haven't responded well to standard lightening creams or peels. It comes in oral, topical, and injectable forms, each with a different balance of convenience, absorption, and risk — none of which work by bleaching pigment directly, unlike most older options.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What Is Tranexamic Acid, and Why Is Dermatology Using It for Melasma?

Tranexamic acid was originally developed decades ago as a medication to reduce excessive bleeding, used in settings ranging from surgery to heavy menstrual periods, and its use in melasma is a newer, repurposed application rather than its original design. Dermatology adopted it, in oral, topical, and injectable forms, largely for melasma that hasn't responded adequately to more established first-line treatments.

It works through a mechanism distinct from most standard melasma treatments, which typically target pigment-producing enzymes directly. That different mechanism is part of why it's often considered as an add-on to, rather than a replacement for, existing approaches, particularly for melasma that has proven stubborn.

Oral vs. Topical: Two Very Different Routes for the Same Drug

The oral tablet and the topical or injectable versions of tranexamic acid behave very differently once they're on or in the body, and that difference is the central trade-off anyone considering it has to weigh. An oral tablet is absorbed into the bloodstream and reaches pigment-producing cells throughout the body, which is part of why it can be effective for widespread or resistant melasma — and also why its safety conversation involves the whole body, not just the treated skin.

That oral-vs-topical calculus isn't unique to melasma. The same trade-off — systemic reach and effect versus a localized application with a generally narrower safety profile — shows up with topical finasteride as an alternative to the oral tablet for hair loss. In both cases, going topical trades some effectiveness or reach for a more contained risk profile.

Why It's Considered for Stubborn Melasma

Tranexamic acid tends to come up specifically for melasma that hasn't responded well to first-line topical treatment or has relapsed after initial improvement, rather than as a starting point for someone newly diagnosed. Its different mechanism is the main rationale: adding a treatment that works through a separate pathway, rather than simply escalating the strength of a pigment-bleaching approach, is a reasonable strategy when the first approach has plateaued.

Where it fits into a broader melasma treatment plan — before, after, or alongside peels for melasma and other options — is usually a decision made after a first-line approach has been given a fair trial and hasn't produced enough change. Some clinicians layer it on as an early addition for melasma that looks likely to be stubborn from the start, based on how deep or extensive the pigment appears; others reserve it strictly as a second-line option once a simpler regimen has already been tried and fallen short. Neither approach is universally right — it depends on the individual case and how much the person is willing to weigh a systemic medication against a topical one.

The Safety Conversation: Why Clotting History Matters

Tranexamic acid's original medical use, reducing bleeding, comes from its effect on the clotting system, and that same mechanism is the center of the safety conversation when it's used for melasma. Oral tranexamic acid is generally avoided in people with a personal or strong family history of blood clots, certain clotting disorders, or a history of stroke, since the drug's clot-stabilizing effect runs counter to what's safe in those situations.

This is also why oral use is typically approached more cautiously than topical or injectable use: a pill reaches the bloodstream directly, while a topical or injected form applied to skin is intended to act more locally. Anyone with a personal or family clotting history, or who is pregnant, generally has that history reviewed carefully — or an alternative route or treatment considered — before oral tranexamic acid is prescribed.

What's Actually Happening in Melasma Itself

Understanding why tranexamic acid is even considered requires understanding what melasma is: an interaction between genetic predisposition, sex hormones, and exposure to ultraviolet and visible light that pushes melanocytes into overproducing pigment in specific, usually symmetric patches 1. It disproportionately affects women and people with darker skin types, and it's notoriously prone to relapse even after successful treatment, which is part of why dermatology keeps expanding its treatment toolkit rather than settling on one standard approach 1.

Hormonal shifts are one of the clearest triggers, which is why melasma so often surfaces or worsens during pregnancy melasma, and why some of the treatments considered for resistant cases, tranexamic acid included, are typically held until after pregnancy and breastfeeding rather than tried during them.

Melasma Isn't the Only Pigment Story: A Quick Contrast

Melasma is a problem of too much pigment in specific patches; it's worth knowing that dermatology also treats the opposite problem, since the two are sometimes confused by anyone searching broadly for skin pigment treatment. Vitiligo is a chronic autoimmune condition where the immune system destroys pigment-producing cells, causing patches that lose color rather than gain it — treated with approaches aimed at restoring pigment, like topical ruxolitinib, which has shown significantly greater repigmentation than a vehicle cream in clinical trials 2, rather than reducing it.

Tranexamic acid has no role in vitiligo, and a treatment aimed at restoring pigment has no role in melasma — the two conditions sit at opposite ends of the same spectrum, and any product or protocol claiming to meaningfully address both at once is worth a second look.

What to Realistically Expect

Tranexamic acid, in whichever form, is not a fast or complete fix — melasma treatment in general tends to be gradual and often requires maintenance to prevent relapse, and tranexamic acid is no exception to that pattern. It's more accurately understood as one tool that can meaningfully help stubborn cases as part of a broader plan, not a standalone cure.

Sun protection remains foundational regardless of which additional treatment is layered on top, since continued UV exposure can undo progress made with any pigment-focused treatment, tranexamic acid included. Anyone considering it is generally better served by a conversation with a dermatologist about personal risk factors and how it fits alongside whatever else is already part of a treatment plan, than by starting it independently.

Common questions

It's generally considered safe for people without a personal or family history of blood clots, stroke, or clotting disorders, since its mechanism affects the clotting system. That history is why prescribers typically screen carefully before starting the oral form in particular.

Topical and oral forms are generally understood to work differently because of how differently they're absorbed — an oral tablet reaches the bloodstream and treats pigment throughout the body, while a topical version acts more locally. Which is more effective for a given case is a question worth discussing directly with a dermatologist.

Melasma treatment in general is gradual rather than fast-acting, and tranexamic acid follows that same pattern. It's typically used over an extended period as part of a broader plan rather than as a short course expected to produce a quick, standalone result.

It's generally held until after pregnancy and breastfeeding, in line with how most active melasma treatments are approached during that time, given both the clotting-risk profile of the oral form and the more general caution clinicians apply to treatments without established pregnancy safety data.

Melasma is prone to relapse after many treatments, including tranexamic acid, especially with continued sun exposure or hormonal triggers. That's part of why it's often used as one piece of an ongoing plan rather than a treatment expected to permanently resolve melasma on its own.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to Loop In a Prescriber Before Starting Tranexamic Acid

  • —A personal or family history of blood clots, stroke, or a known clotting disorder
  • —Current pregnancy or a history of hormone-related clotting risk
  • —Leg swelling, pain, or redness, sudden shortness of breath, or chest pain while taking oral tranexamic acid

Sudden leg swelling and pain, chest pain, or unexplained shortness of breath while taking oral tranexamic acid warrants prompt medical evaluation — calling 911 or going to the nearest emergency room rather than waiting for a scheduled visit.

This article is educational and does not replace a conversation with a prescribing clinician, who can review personal and family clotting history before starting tranexamic acid in any form.

References

  1. 1.Sheth VM, Pandya AG (2011). Melasma: a comprehensive update: part I. Journal of the American Academy of Dermatology. PMID 21920241 ✓Review of melasma epidemiology and pathogenesis: the interaction of genetic predisposition, sex hormones, and UV/visible-light exposure, and its predilection for women and darker skin types, used here to explain why melasma is prone to relapse and why dermatology has expanded its treatment toolkit.
  2. 2.Rosmarin D, Passeron T, Pandya AG, et al. (2022). Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. doi:10.1056/NEJMoa2118828 ✓TRuE-V1 and TRuE-V2 phase 3 trials showing topical ruxolitinib produces significantly greater repigmentation than vehicle in vitiligo, used here purely as a contrast to melasma: a treatment that restores lost pigment for a condition with the opposite pigment problem from melasma.

2 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library